Leng-Chen Hou1, Fang Huang2, Hong-Bin Xu2. 1. Department of Anesthesia, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, 200072, China. 2. Department of Pharmacy, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, 200072, China.
Abstract
AIMS: Clinical trials have reported conflicting results about whether celecoxib plus chemotherapy improves outcomes over chemotherapy alone in patients with advanced non-small cell lung cancer. METHODS: We performed a meta-analysis comparing the primary and secondary endpoints of treatment with celecoxib plus chemotherapy vs. chemotherapy alone in patients with advanced non-small cell lung cancer. RESULTS: Six eligible trials (1181 patients) were selected from the 206 studies that were identified initially. A significant difference, favouring celecoxib plus chemotherapy over chemotherapy alone, was observed in the overall response rate [odds ratio (OR) 1.34; 95% confidence interval (CI) 1.08, 1.67; P = 0.009). However, there was no difference in the 1-year survival rate (OR 1.08; 95% CI 0.86, 1.35; P = 0.512), clinical benefit (OR 1.05; 95% CI 1.88, 1.25; P = 0.613), complete response (OR 0.77; 95% CI 0.39, 1.51; P = 0.446) or partial response (OR 1.22; 95% CI 0.92, 1.63; P = 0.163). Toxicity did not differ significantly with the exception of the occurrence of leucopenia and thrombocytopenia. CONCLUSIONS: Celecoxib plus chemotherapy appeared to improve the overall response rate compared with chemotherapy alone in the treatment of patients with advanced non-small cell lung cancer. Further prospective randomized controlled trials are now needed.
AIMS: Clinical trials have reported conflicting results about whether celecoxib plus chemotherapy improves outcomes over chemotherapy alone in patients with advanced non-small cell lung cancer. METHODS: We performed a meta-analysis comparing the primary and secondary endpoints of treatment with celecoxib plus chemotherapy vs. chemotherapy alone in patients with advanced non-small cell lung cancer. RESULTS: Six eligible trials (1181 patients) were selected from the 206 studies that were identified initially. A significant difference, favouring celecoxib plus chemotherapy over chemotherapy alone, was observed in the overall response rate [odds ratio (OR) 1.34; 95% confidence interval (CI) 1.08, 1.67; P = 0.009). However, there was no difference in the 1-year survival rate (OR 1.08; 95% CI 0.86, 1.35; P = 0.512), clinical benefit (OR 1.05; 95% CI 1.88, 1.25; P = 0.613), complete response (OR 0.77; 95% CI 0.39, 1.51; P = 0.446) or partial response (OR 1.22; 95% CI 0.92, 1.63; P = 0.163). Toxicity did not differ significantly with the exception of the occurrence of leucopenia and thrombocytopenia. CONCLUSIONS:Celecoxib plus chemotherapy appeared to improve the overall response rate compared with chemotherapy alone in the treatment of patients with advanced non-small cell lung cancer. Further prospective randomized controlled trials are now needed.
Authors: Francis W Nugent; Wilson C Mertens; Stephen Graziano; Nathan Levitan; Rufus Collea; Ajeet Gajra; Janine Marshall; John McCann Journal: Lung Cancer Date: 2005-05 Impact factor: 5.705
Authors: Harry J M Groen; Hannie Sietsma; Andrew Vincent; Monique M H Hochstenbag; John W G van Putten; Anke van den Berg; Otilia Dalesio; Bonne Biesma; Hans J M Smit; Ariën Termeer; T Jeroen N Hiltermann; Ben E E M van den Borne; Franz M N H Schramel Journal: J Clin Oncol Date: 2011-10-11 Impact factor: 44.544
Authors: N K Altorki; R S Keresztes; J L Port; D M Libby; R J Korst; D B Flieder; C A Ferrara; D F Yankelevitz; K Subbaramaiah; M W Pasmantier; A J Dannenberg Journal: J Clin Oncol Date: 2003-07-15 Impact factor: 44.544
Authors: Martin J Edelman; Dee Watson; Xiaofei Wang; Carl Morrison; Robert A Kratzke; Scott Jewell; Lydia Hodgson; Ann M Mauer; Ajeet Gajra; Gregory A Masters; Michelle Bedor; Everett E Vokes; Mark J Green Journal: J Clin Oncol Date: 2008-02-20 Impact factor: 44.544
Authors: Hazel R Scott; Donald C McMillan; Duncan J F Brown; Lynn M Forrest; Colin S McArdle; Robert Milroy Journal: Lung Cancer Date: 2003-06 Impact factor: 5.705